Citius Pharmaceuticals to Present at Noble Capital Markets' 16th Annual Investor Conference
CRANFORD, N.J., Feb. 10, 2020 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (NASDAQ: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, announced today that the Company will present at Noble Capital Markets' 16th Annual Investor Conference on Monday, February 17, 2020 at 4:00 PM ET. The conference is being held at the Seminole Hard Rock Hotel & Casino in Hollywood, Florida on February 16-18, 2020.
Event: Noble Capital Markets' 16th Annual Investor Conference
Presentation Date: Monday, February 17, 2020
Presentation Time: 4:00 PM ET – Terrace Ballroom A
Location: Seminole Hard Rock Hotel & Casino – Hollywood, FL
Mr. Leonard Mazur, Chairman of Citius, will deliver an update on the Company, including a discussion of the recent positive outcome of its interim futility analysis for the Phase 3 Mino-Lok® pivotal trial, and provide an overview of its other pipeline products, Mino-Wrap™ and Halo-Lido. Additionally, Mr. Mazur will also be available at the conference for one-on-one meetings with investors. To arrange a meeting with the Company, please contact Mr. Andrew Scott: firstname.lastname@example.org.
Mr. Mazur's presentation will be available for playback at the link below approximately 24 hours following his live address and be archived for 90 days following the conference: http://noble.mediasite.com/Mediasite/Play/838b6f0a3a53473cbd89e1507a111a411d
This is the 16th year Noble Capital Markets has hosted "NobleCon" and invited emerging growth companies to present to and meet with attending investors. NobleCon will feature approximately 125 small growth companies presenting across four tracks occurring simultaneously, company executives meeting with investors in 1x1/face-to-face formats, and special panel sessions featuring key opinion leaders on topics such as cannabis, biotechnology, and mining, just to name a few. Noble Capital Markets will be broadening access to investors worldwide by hosting the conference site on Channelchek.com, its web-based market platform that emphasizes emerging growth companies.
About Citius Pharmaceuticals, Inc.
Citius is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products, with a focus on anti-infectives, cancer care, and unique prescription products that use innovative, patented, or proprietary formulations of previously-approved active pharmaceutical ingredients. We seek to achieve leading market positions by providing therapeutic products that address unmet medical needs. By using previously approved drugs with substantial safety and efficacy data, we seek to reduce the risks associated with pharmaceutical product development and regulatory requirements. Citius develops products that have intellectual property protection and competitive advantages to existing therapeutic approaches. For more information, please visit www.citiuspharma.com.
This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are made based on our expectations and beliefs concerning future events impacting Citius. You can identify these statements by the fact that they use words such as "will," "anticipate," "estimate," "expect," "should," and "may" and other words and terms of similar meaning or use of future dates. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated are: risks associated with conducting our Phase 3 trial for Mino-Lok, including completing patient enrollment, opening study sites and achieving the required number of catheter failure events; the estimated markets for our product candidates and the acceptance thereof by any market; our need for substantial additional funds; risks associated with developing Mino-Wrap, including that preclinical results may not be predictive of clinical results and our ability to file an IND; risks related to our growth strategy; our ability to identify, acquire, close and integrate product candidates and companies successfully and on a timely basis; risks relating to the results of research and development activities; uncertainties relating to preclinical and clinical testing; the early stage of products under development; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; our ability to attract, integrate, and retain key personnel; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.
Vice President, Corporate Development
(O) 908-967-6677 x105
SOURCE Citius Pharmaceuticals, Inc.
Released February 10, 2020